Pfm Health Sciences, LP Karuna Therapeutics, Inc. Transaction History

Pfm Health Sciences, LP

$1.95 Billion
Q2 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$161.01 - $317.85 $1.27 Million - $2.52 Million	-7,916 Reduced 5.73%	130,293 $41.2 Million
Q1 2023 May 15, 2023	BUY	$161.33 - $204.36 $1.28 Million - $1.62 Million	7,916 Added 6.08%	138,209 $25.1 Million
Q2 2022 Aug 15, 2022	SELL	$93.97 - $143.33 $7.22 Million - $11 Million	-76,823 Reduced 37.09%	130,293 $16.5 Million
Q1 2022 May 16, 2022	BUY	$98.9 - $132.37 $2.97 Million - $3.97 Million	30,025 Added 16.95%	207,116 $26.3 Million
Q3 2021 Nov 15, 2021	SELL	$101.2 - $125.87 $1.65 Million - $2.05 Million	-16,295 Reduced 8.43%	177,091 $21.7 Million
Q2 2021 Aug 16, 2021	BUY	$107.45 - $135.95 $1.56 Million - $1.98 Million	14,540 Added 8.13%	193,386 $22 Million
Q1 2021 May 17, 2021	BUY	$95.46 - $133.08 $17.1 Million - $23.8 Million	178,846 New	178,846 $21.5 Million
Q4 2020 Feb 16, 2021	SELL	$75.23 - $109.23 $10.4 Million - $15.1 Million	-137,960 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$71.31 - $109.74 $15.3 Million - $23.5 Million	-214,585 Reduced 60.87%	137,960 $10.7 Million
Q2 2020 Aug 14, 2020	SELL	$62.14 - $117.21 $9.13 Million - $17.2 Million	-146,965 Reduced 29.42%	352,545 $39.3 Million
Q1 2020 May 15, 2020	SELL	$60.41 - $115.92 $6.22 Million - $11.9 Million	-103,041 Reduced 17.1%	499,510 $36 Million
Q4 2019 Feb 14, 2020	BUY	$11.44 - $123.99 $2.2 Million - $23.8 Million	191,908 Added 46.73%	602,551 $45.4 Million
Q3 2019 Nov 14, 2019	SELL	$16.05 - $27.35 $5.82 Million - $9.91 Million	-362,388 Reduced 46.88%	410,643 $6.7 Million
Q2 2019 Aug 14, 2019	BUY	$20.02 - $20.02 $15.5 Million - $15.5 Million	773,031 New	773,031 $14.2 Million

Others Institutions Holding KRTX

# of Institutions

Shares Held

332K

Call Options Held

Put Options Held

View Full List

About Karuna Therapeutics, Inc.

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

More about KRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

News

Stay updated on Pfm Health Sciences, LP with notifications on news.

Account